FMC appoints Korangy as CEO: what it means for FMC stock
Published on 10/17/2026 at 10:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLeadership change and company priorities
- Fresenius Medical Care announced the appointment of Shervin Korangy on October 7, 2026.
- Korangy, 51, became CEO and Chair of the Management Board on October 12, 2026.
- The company said its FME25+ transformation reduced its cost base by around EUR 1.20 billion.
Fresenius Medical Care announced on October 7, 2026, that Shervin J. Korangy would become Chief Executive Officer and Chair of the Management Board effective October 12, 2026, succeeding Helen Giza, according to the company’s press release.
Market context: Market report DAX.
Leadership transition
Korangy, 51, had served on Fresenius Medical Care’s Supervisory Board since 2023 and resigned from that position in connection with his appointment. The company said the Supervisory Board identified Ann Custin as a successor, with court proceedings to appoint her to be initiated in due course. These details were provided in the company’s release.
Transformation and priorities
Fresenius Medical Care said its FME25+ transformation program reshaped the organization, streamlined processes and reduced its cost base by around EUR 1.20 billion. The company said its next phase will focus on accelerating long-term profitable growth, advancing innovation and strengthening market leadership, according to the company announcement.
Next Xetra session
The next Xetra session is scheduled for October 19, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of FMC stock.
